Tuberc Respir Dis > Accepted Articles
DOI: https://doi.org/10.4046/trd.2022.0066    [Accepted]
Published online October 5, 2022.
New targeted therapy for Non-small cell lung cancer
Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee
Division of Pulmonary, Department of Internal Medicine, Yonsei University College of medicine
Correspondence:  Sang Hoon Lee, Tel: 82-2-2228-1941, Fax: 82-2-2228-1932, 
Email: cloud9@yuhs.ac
Received: 2 May 2022   • Revised: 27 June 2022   • Accepted: 3 October 2022
Abstract
Lung cancer ranks first in cancer mortality in Korea and in cancer incidence in Korean men. More than half of the Korean lung cancer patients are subjected to chemotherapy including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previous targeted therapies have been developed for common genetic mutations, recent targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since the use of previous targeted treatments and have also been developed for gene mutations such as KRAS, which are common but have not been developed due to development difficulties. Therefore, in this study, we describe the recent, rapidly developing target agents.
Key Words: Target therapy, Non-small cell lung cancer, Prognosis


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2022 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next